SCHEMBL13189554

SCHEMBL13189554

Cc1cc(NC(=O)c2cc(Cl)ccc2O)cc(C(F)(F)F)c1

nearest known ligand 0.83

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TMPRSS4 Q9NRS4 16/20 0.83
P2RX1 P51575 12/20 0.83
P2RX4 Q99571 7/20 0.83
P2RX7 Q99572 7/20 0.83
MEN1 O00255 1/20 0.83
IKBKB O14920 1/20 0.83
CHUK O15111 1/20 0.83
KDR P35968 1/20 0.83
FLT3 P36888 1/20 0.83
KMT2A Q03164 1/20 0.83
MYLK Q15746 1/20 0.83
MAP4K5 Q9Y4K4 1/20 0.83
SLC2A1 P11166 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Imd-0354 SCHEMBL29406220 0.91 TMPRSS4 (1.00) TMPRSS4P2RX1P2RX4P2RX7MEN1
Imd-0354 SCHEMBL129165 0.91 TMPRSS4 (1.00) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL13812702 0.91 TMPRSS4 (0.94) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL330059 0.88 TMPRSS4 (0.90) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL16707254 0.88 TMPRSS4 (0.88) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL30087053 0.87 TMPRSS4 (0.74) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL11932157 0.87 P2RX1 (1.00) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL30100386 0.86 TMPRSS4 (0.85) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL131758 0.86 TMPRSS4 (0.85) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL30100462 0.86 TMPRSS4 (0.85) TMPRSS4P2RX1P2RX4P2RX7MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180169118-A1 NOVEL PRODRUG SALTS AEROMICS, INC. (US) 2018-06-21 US disclosed
WO-2010101648-A1 GLUTAMATE RECEPTOR MODULATORS AND THERAPEUTIC AGENTS WOOD RICHARD D (US) 2010-09-10 WO disclosed
US-20090239919-A1 Glutamate receptor modulators and therapeutic agents WOOD RICHARD DELAREY 2009-09-24 US disclosed
US-20090239919-A1 Glutamate receptor modulators and therapeutic agents WOOD RICHARD DELAREY 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239919-A1 Glutamate receptor modulators and therapeutic agents GRM5, GRM1, GRIK5 TMPRSS4 2378/4885P2RX1 542/4885P2RX4 611/4885
US-20180169118-A1 NOVEL PRODRUG SALTS AQP4, AQP1, AQP3 TMPRSS4 1033/4885P2RX1 543/4885P2RX4 640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.